DSS (DSS) 10-Q 14 May 24 2024 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2024	May 03, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-32146
Entity Registrant Name	DSS, INC.
Entity Central Index Key	0000771999
Entity Tax Identification Number	16-1229730
Entity Incorporation, State or Country Code	NY
Entity Address, Address Line One	275 Wiregrass Pkwy
Entity Address, City or Town	West Henrietta
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	14586
City Area Code	(585)
Local Phone Number	325-3610
Title of 12(b) Security	Common Stock, $0.02 par value per share
Trading Symbol	DSS
Security Exchange Name	NYSEAMER
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		7,066,772

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 9,252,000	$ 6,615,000
Accounts receivable, net	2,863,000	3,994,000
Inventory	3,627,000	2,819,000
Assets held for sale	51,624,000	51,595,000
Current portion of notes receivable	4,062,000	8,772,000
Prepaid expenses and other current assets	736,000	839,000
Total current assets	72,164,000	74,634,000
Property, plant and equipment, net	6,225,000	6,417,000
Investment in real estate, net	6,252,000	6,279,000
Other investments	1,282,000	1,282,000
Investment, equity method	127,000	128,000
Marketable securities	8,483,000	9,979,000
Notes receivable	87,000	111,000
Other assets	133,000	97,000
Right-of-use assets	7,026,000	7,210,000
Goodwill	26,862,000	26,862,000
Other intangible assets, net	19,859,000	20,193,000
Total assets	148,500,000	153,192,000
Current liabilities:
Accounts payable	4,084,000	3,654,000
Accrued expenses and deferred revenue	3,004,000	2,512,000
Other current liabilities	932,000	983,000
Current portion of lease liability	684,000	686,000
Current portion of long-term debt, net	47,509,000	47,776,000
Total current liabilities	56,213,000	55,611,000
Long-term debt, net	7,431,000	7,451,000
Long term lease liability	6,752,000	6,917,000
Commitments and contingencies (Note 11)
Stockholders’ equity
Preferred stock, $0.02 par value; 47,000 shares authorized, zero shares issued and outstanding (zero on December 31, 2023); Liquidation value $1,000 per share, zero aggregate. zero on December 31, 2023).
Common stock, $0.02 par value; 200,000,000 shares authorized, 7,066,772 shares issued and outstanding (7,066,772 on December 31, 2023)	140,000	140,000
Additional paid-in capital	319,963,000	319,963,000
Accumulated deficit	(260,248,000)	(256,176,000)
Total DSS stockholders’ equity	59,855,000	63,927,000
Non-controlling interest in subsidiaries	18,249,000	19,286,000
Total stockholders’ equity	78,104,000	83,213,000
Total liabilities and stockholders’ equity	$ 148,500,000	$ 153,192,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.02	$ 0.02
Preferred stock, shares authorized	47,000	47,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred stock, liquidation preference per share	$ 1,000	$ 1,000
Preferred stock, liquidation preference	$ 0	$ 0
Common stock, par value	$ 0.02	$ 0.02
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	7,066,772	7,066,772
Common stock, shares outstanding	7,066,772	7,066,772

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 3,871,000	$ 11,926,000
Costs and expenses:
Cost of revenue	4,990,000	8,533,000
Selling, general and administrative	3,561,000	8,973,000
Total costs and expenses	8,551,000	17,506,000
Operating loss	(4,680,000)	(5,580,000)
Other income (expense):
Interest income	107,000	130,000
Dividend income		4,000
Other income (expense)	21,000	(65,000)
Interest expense	(48,000)	(249,000)
Loss on equity method investment	(1,000)	(4,000)
Loss on investments	(189,000)	(2,869,000)
Provision for loan losses	(294,000)
Loss from operations before income taxes	(5,084,000)	(8,633,000)
Income tax loss	(25,000)
Net loss	(5,109,000)	(8,633,000)
Loss from operations attributed to noncontrolling interest	1,037,000	598,000
Net loss attributable to DSS common stockholders	$ (4,072,000)	$ (8,035,000)
Loss per common share:
Basic	$ (0.58)	$ (1.16)
Diluted	$ (0.58)	$ (1.16)
Shares used in computing loss per common share:
Basic	7,066,772	6,950,858
Diluted	7,066,772	6,950,858
Printed Products [Member]
Revenue:
Total revenue	$ 3,073,000	$ 6,130,000
Rental Income [Member]
Revenue:
Total revenue	400,000	1,685,000
Net Investment Income [Member]
Revenue:
Total revenue	95,000	117,000
Direct Marketing [Member]
Revenue:
Total revenue		3,994,000
Commission Revenue [Member]
Revenue:
Total revenue	$ 303,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Loss from continuing operations	$ (5,109,000)	$ (8,633,000)
Adjustments to reconcile loss from continuing operations to net cash used by operating activities:
Depreciation and amortization	582,000	1,333,000
Loss on equity method investment	1,000
Loss on investments	189,000	2,869,000
Change in ROU assets	184,000	16,000
Provision for loan losses	763,000
Decrease (increase) in assets:
Accounts receivable	1,347,000	608,000
Inventory	(808,000)	459,000
Prepaid expenses and other current assets	36,000	(383,000)
Other assets	(36,000)	(55,000)
Increase (decrease) in liabilities:
Accounts payable	430,000	(819,000)
Accrued expenses	489,000	(9,551,000)
Change in ROU liabilities	(167,000)	(43,000)
Other liabilities	(51,000)
Net cash used by operating activities	(2,150,000)	(14,199,000)
Cash flows from investing activities:
Purchase of property, plant and equipment	(3,000)	(594,000)
Purchase of investment	(31,000)
Disposal of property, plant and equipment		32,000
Change in equity investment		5,000
Sale of marketable securities	1,160,000	11,330,000
Payments received on notes receivable	3,971,000	764,000
Net cash provided by investing activities	5,097,000	11,537,000
Cash flows from financing activities:
Payments of long-term debt	(1,062,000)	(4,002,000)
Borrowings of long-term debt	752,000	1,106,000
Net cash used by financing activities	(310,000)	(2,896,000)
Net increase (decrease) in cash	2,637,000	(5,558,000)
Cash and cash equivalents at beginning of period	6,615,000	19,290,000
Cash and cash equivalents at end of period	$ 9,252,000	$ 13,732,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Parent [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2022	$ 139,000		$ 319,766,000	$ (194,343,000)	$ 125,562,000	$ 31,119,000	$ 156,681,000
Balance, shares at Dec. 31, 2022	6,950,858
Net loss				(8,035,000)	(8,035,000)	(598,000)	(8,633,000)
Balance at Mar. 31, 2023	$ 139,000		319,766,000	(202,378,000)	117,527,000	30,521,000	148,048,000
Balance, shares at Mar. 31, 2023	6,950,858
Balance at Dec. 31, 2023	$ 140,000		319,963,000	(256,176,000)	63,927,000	19,286,000	83,213,000
Balance, shares at Dec. 31, 2023	7,066,772
Net loss				(4,072,000)	(4,072,000)	(1,037,000)	(5,109,000)
Balance at Mar. 31, 2024	$ 140,000		$ 319,963,000	$ (260,248,000)	$ 59,855,000	$ 18,249,000	$ 78,104,000
Balance, shares at Mar. 31, 2024	7,066,772

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	1. Basis of Presentation and Significant Accounting Policies The Company, incorporated in the state of New York in May 1984 has conducted business in the name of DSS, Inc. On September 16, 2021, the board of directors approved an agreement and plan of merger with a wholly owned subsidiary, DSS, Inc. (a New York corporation, incorporated in August 2020), for the sole purpose of effecting a name change from Document Security Systems, Inc. to DSS, Inc. This change became effective on September 30, 2021. DSS, Inc. maintained the same trading symbol “DSS”. DSS, Inc. (together with its consolidated subsidiaries, referred to herein as “DSS,” “we,” “us,” “our” or the “Company”), currently operates nine (9) distinct business lines with operations and locations around the globe. These business lines are: (1) Product Packaging, (2) Biotechnology, (3) Direct, (4) Commercial Lending, (5) Securities and Investment Management, (6) Alternative Trading (7) Digital Transformation (discontinued in 2023), (8) Secure Living (discontinued in 2023), and (9) Alternative Energy (discontinued in 2023). Each of these business lines are in different stages of development, growth, and income generation. Our divisions, their business lines, subsidiaries, and operating territories: (1) Our Product Packaging line is led by Premier Packaging Corporation, Inc. (“Premier”), a New York corporation. Premier operates in the paper board and fiber based folding carton, consumer product packaging, and document security printing markets. It markets, manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex 3-dimensional direct mail solutions. Premier is currently located in its new facility in Rochester, NY, and primarily serves the US market. (2) The Biotechnology business line was created to invest in or acquire companies in the BioHealth and BioMedical fields, including businesses focused on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. This division is also targeting unmet, urgent medical needs, and is developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. (3) Direct Marketing, led by the holding corporation, Decentralized Sharing Systems, Inc. (“Decentralized”) provides services to assist companies in the emerging growth “Gig” business model of peer-to-peer decentralized sharing marketplaces. Direct Marketing’s products include, among other things, nutritional and personal care products sold throughout North America, Asia Pacific, Middle East, and Eastern Europe. (4) Our Commercial Lending business division, driven by American Pacific Bancorp (“APB”), is organized for the purposes of being a financial network holding company, focused on acquiring equity positions in (i) undervalued commercial bank(s), bank holding companies and nonbanking licensed financial companies operating in the United States, South East Asia, Taiwan, Japan and South Korea, and (ii) companies engaged in—nonbanking activities closely related to banking, including loan syndication services, mortgage banking, trust and escrow services, banking technology, loan servicing, equipment leasing, problem asset management, SPAC (special purpose acquisition company) consulting services, and advisory capital raising services. (5) Securities and Investment Management was established to develop and/or acquire assets in the securities trading or management arena, and to pursue, among other product and service lines, broker dealers, and mutual funds management. Also in this segment is the Company’s real estate investment trusts (“REIT”), organized for the purposes of acquiring hospitals and other acute or post-acute care centers from leading clinical operators with dominant market share in secondary and tertiary markets, and leasing each property to a single operator under a triple-net lease. the REIT was formed to originate, acquire, and lease a credit-centric portfolio of licensed medical real estate. (6) Alternative Trading was established to develop and/or acquire assets and investments in the securities trading and/or funds management arena. Alternative Trading, in partnership with recognized global leaders in alternative trading systems, intends to own and operate in the US a single or multiple vertical digital asset exchanges for securities, tokenized assets, utility tokens, and cryptocurrency via an alternative trading platform using blockchain technology. The scope of services within this section is planned to include asset issuance and allocation (securities and cryptocurrency), FPO, IPO, ITO, PPO, and UTO listings on a primary market(s), asset digitization/tokenization (securities, currency, and cryptocurrency), and the listing and trading of digital assets (securities and cryptocurrency) on a secondary market(s). (7) Digital Transformation was established to be a Preferred Technology Partner and Application Development Solution for mid cap brands in various industries including the direct selling and affiliate marketing sector. Digital improves marketing, communications and operations processes with custom software development and implementation (discontinued in 2023). (8) The Secure Living division has developed a plan for fully sustainable, secure, connected, and healthy living communities with homes incorporating advanced technology, energy efficiency, and quality of life living environments both for new construction and renovations for single and multi-family residential housing (discontinued in 2023). (9) The Alternative Energy group was established to help lead the Company’s future in the clean energy business that focuses on environmentally responsible and sustainable measures. Alset Energy, Inc, the holding company for this group, and its wholly owned subsidiary, Alset Solar, Inc., pursue utility-scale solar farms to serve US regional power grids and to provide underutilized properties with small microgrids for independent energy (discontinued in 2023). The accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments, unless otherwise indicated) necessary to present fairly our consolidated financial position as of March 31, 2024 and December 31, 2023, and the results of our consolidated operations for the interim periods presented. We follow the same accounting policies when preparing quarterly financial data as we use for preparing annual data. These statements should be read in conjunction with the consolidated financial statements and the notes included in our latest annual report on Form 10-K, for the fiscal year ended December 31, 2023 (“Form 10-K”), and our other reports on file with the Securities and Exchange Commission (the “SEC”). Principles of Consolidation Deconsolidation of Sharing Services Global Corporation(“SHRG”) 280 7 81 s a result, SHRG, whose operations represented a significant portion of our Direct Marketing segment, was deconsolidated from our consolidated financial statements effective as of May 1, 2023 (the “Deconsolidation”). The consolidated statement of operations for the fiscal quarter ended September 30, 2023, therefore includes one month of activity related to SHRG prior to the Deconsolidation. Subsequent to April 30, 2023 the assets and liabilities of SHRG are no longer included within our consolidated balance sheets. Any discussions related to results, operations, and accounting policies associated with SHRG refer to the periods prior to the Deconsolidation. Upon Deconsolidation, we recognized a loss before income taxes of approximately $ 29,196,000 Use of Estimates Cash Equivalents Accounts/Rents Receivable At March 31, 2024, and December 31, 2023, the Company established a reserve for credit losses of approximately $ 2,492,000 2,494,000 Concentration of Credit Risk - The Company maintains its cash in bank deposit accounts, which at times may exceed federally insured limits. The Company believes it is not exposed to any significant credit risk because of any non-performance by the financial institutions. As of March 31, 2024, one customers accounted for approximately 25 % of our consolidated revenue. As of March 31, 2024, one customers accounted for approximately 44 % of our trade accounts receivable balance. As of December 31, 2023, two customers accounted for approximately 20 % and 11 % of our consolidated revenue and 39 % and 30 % of our trade accounts receivable balance. As of March 31, 2024 and 2023, one vendor accounted for approximately 16 11 Notes receivable, unearned interest, and related recognition Allowance For Loans And Lease Losses ASU No.2016-13 – Credit Losses” Investments Fair Value of Financial Instruments - ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts reported in the consolidated balance sheet of cash and cash equivalents, accounts receivable, prepaids, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. Marketable securities classify as a Level 1 fair value financial instrument. The fair value of notes receivable approximates their carrying value as the stated or discounted rates of the notes do not reflect recent market conditions. The fair value of revolving credit lines notes payable and long-term debt approximates their carrying value as the stated or discounted rates of the debt reflect recent market conditions. The fair value of investments where the fair value is not considered readily determinable, are carried at cost. Inventory 15,000 18,000 Investments in real estate, net Assets held for sale 5,593,000 41,570,000 4,396,000 65,000 Intangible Assets 7,418,000 Goodwill 1,769,000 25,093,000 29,744,000 1,234,000 Impairment of Long-Lived Assets and Goodwill Business Combinations Loss Per Common Share 5,000 0 Income Taxes Going Concern 9.3 Aside from its $ 9.3 8.5 723,000 51.6

Revenue

Revenue	3 Months Ended
	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
Revenue	2. Revenue The Company recognizes its revenue based on when the title passes to the customer or when the service is completed and accepted by the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for shipped product or service provided. Sales and other taxes billed and collected from customers are excluded from revenue. The Company recognizes rental income associated with its REIT, net of amortization of favorable/unfavorable lease terms relative to market and includes rental abatements and contractual fixed increases attributable to operating leases, where collection has been considered probable, on a straight-line basis over the term of the related lease. The Company recognizes net investment income from its investment banking line of business as interest and management fees related to loans managed for third parties owed to the Company occurs. The Company generates revenue from its direct marketing line of business primarily through internet sales and recognizes revenue as items are shipped. As of March 31, 2024, the Company had no unsatisfied performance obligations for contracts with an original expected duration of greater than one year. Pursuant to Topic 606, the Company has applied the practical expedient with respect to disclosure of the deferral and future expected timing of revenue recognition for transaction price allocated to remaining performance obligations. The Company elected the practical expedient allowing it to not recognize as a contract asset the commission paid to its salesforce on the sale of its products as an incremental cost of obtaining a contract with a customer but rather recognize such commission as expense when incurred as the amortization period of the asset that the Company would have otherwise recognized is one year or less. Sales Commissions Sales commissions are expensed as incurred for contracts with an expected duration of one year or less. There were no sales commissions capitalized as of March 31, 2024 or March 31, 2023. Shipping and Handling Costs Costs incurred by the Company related to shipping and handling are included in cost of products sold. Amounts charged to customers relating to these costs are reflected as revenue. See Note 14 for disaggregated revenue information.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2024
Inventory Disclosure [Abstract]
Inventory	3. Inventory Inventory consisted of the following as of: Schedule of Inventory March December 2024 2023 Finished Goods $ 2,318,000 $ 2,218,000 Work in Process 845,000 180,000 Raw Materials 479,000 439,000 Inventory Gross $ 3,642,000 $ 2,837,000 Less allowance for obsolescence (15,000 ) (18,000 ) Inventory Net $ 3,627,000 $ 2,819,000

Notes Receivable

Notes Receivable	3 Months Ended
	Mar. 31, 2024
Receivables [Abstract]
Notes Receivable	4. Notes Receivable Note 1 On May 14, 2021, DSS Pure Air, Inc. a subsidiary of the Company entered a convertible promissory note (“Note 1”) with Borrower 1, a company registered in the state of Texas. Note 1 has an aggregate principal balance up to $ 5,000,000 6.65 Note 1 contains an optional conversion clause that allows the Company to convert all, or a portion of all, into newly issued member units of Borrower 1 with the maximum principal amount equal to 18% of the total equity position of Borrower 1 at conversion 5,544,000 2,772,000 2,772,000 Note 2 On September 23, 2021, APB entered into refunding bond anticipatory note (“Note 2”) with Borrower 2, which operates as a conservation and reclamation district pursuant to Chapter 3891, Texas Special District Local Laws Code; Chapter 375, Texas Local Government Code; and Chapter 49, Texas Water Code. The District Note was in the sum of $ 3,500,000 5.59 3,910,000 Note 3 On October 25, 2021, APB entered into a loan agreement (“Note 3”) with Borrower 3, a company registered in the state of Utah. Note 3 has an initial aggregate principal balance up to $ 1,000,000 3,000,000 8.0 October 25, 2022 884,000 Note 4 On December 28, 2021, APB entered into a promissory note (“Note 4”) with Borrower 4, a company registered in the state of California. Note 4 has a principal balance of $ 700,000 12.0 December 28, 2022 May 31, 2023 50,000 158,000 253,000 Note 5 On January 24, 2022, APB and Borrower 5 entered into a promissory note (“Note 5”) in the principal sum of $ 100,000 6 January 2024 107,000 103,000 Note 6 On March 2, 2022, APB and Borrower 6, a corporation organized under the laws of the Republic of Korea entered into a promissory note (“Note 6”). Under the terms of Note 6, APB at its discretion, may lend up to the principal sum of $ 893,000 8 March 2024 458,000 446,000 3,500 Note 7 On May 9, 2022, DSS PureAir and Borrower 1 entered into a promissory note (“Note 7”) in the principal sum of $ 210,000 10 February 9, 2023 224,000 112,000 Note 8, related party On August 29, 2022, DSS Financial Management Inc and Borrower 8, a related party, entered into a promissory note (“Note 8”) in the principal sum of $ 100,000 8 August 29, 2025 101,000 76,000 100,000 76,000 24,000 24.9 Note 9, related party On May 8, 2023, DSS Financial Management Inc and Borrower 8 entered into a promissory note (“Note 9”) in the principal sum of $ 102,000 2 10.5 May 7, 2026 110,000 82,000 28,000 107,000 53,000 54,000 24.9 Note 10, related party On July 26, 2022, APB and Borrower 10 entered into a promissory note (“Note 10”) in the principal sum of $ 1,000,000 8 July 26, 2024 949,000 10,000 475,000 939,000 20,000 Note 11 On February 19, 2021, Impact BioMedical, Inc, entered into a promissory note with an individual. The Company loaned the principal sum of $ 206,000 6.5 August 19, 2022 203,000 Note 12 On June 27, 2023, DSS and Borrower 15 entered into a convertible promissory note (“Note 15”) in the principal sum of $ 1,400,000 300,000 10 September 1, 2024 Note 13 On March 31,2023, DSS Biohealth Security, Inc and Borrower 13 entered into a promissory note (“Note 13”) in the principal sum of $ 140,000 8.5 March 31, 2025 133,000 99,000 34,000 135,000

Financial Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2024
Investments, All Other Investments [Abstract]
Financial Instruments	5. Financial Instruments Cash, Cash Equivalents, Restricted Cash and Marketable Securities The following tables show the Company’s cash, cash equivalents, restricted cash, and marketable securities by significant investment category as of March 31, 2024 and December 31, 2023: Schedule of Cash and Marketable Securities by Significant Investment Category 2024 cost Unrealized Gain/(Loss) Fair Value Cash and Cash Equivalents Marketable Securities Cash $ 9,182,000 $ - $ 9,182,000 $ 9,182,000 $ - Level 1 Money Market Funds 70,000 - 70,000 70,000 - Marketable Securities 26,629,000 (17,146,000 ) 8,483,000 - 8,483,000 Total $ 34,881,000 $ (17,146,000 ) $ 17,735,000 $ 9,252,000 $ 8,483,000 2023 Adjusted Cost Unrealized Gain/(Loss) Fair Value Cash and Cash Equivalents Marketable Securities Cash $ 6,545,000 $ - $ 6,545,000 $ 6,545,000 $ - Level 1 Money Market Funds $ 70,000 - $ 70,000 70,000 - Marketable Securities $ 27,304,000 (17,325,000 ) $ 9,979,000 - 9,979,000 Total $ 33,919,000 $ (17,325,000 ) $ 16,594,000 $ 6,615,000 $ 9,979,000 The Company typically invests with the primary objective of minimizing the potential risk of principal loss. The Company’s investment policy generally requires securities to be investment grade and limits the amount of credit exposure to any one issuer. Fair values were determined for each individual security in the investment portfolio.

Provision for Credit Losses

Provision for Credit Losses	3 Months Ended
	Mar. 31, 2024
Provision For Credit Losses
Provision for Credit Losses	6. Provision for Credit Losses Effective January 1, 2022, the Company adopted amended accounting guidance “ ASU No.2016-13 – Credit Losses” Accounts receivable are stated at the amount owed by the customer. The Company maintains an allowance for credit losses for accounts receivable and unbilled receivables, based on expected credit losses resulting from the inability of our customers to make required payments. The allowance for credit losses is estimated based on historical experience, current economic conditions and the creditworthiness of customers. Receivables are charged to the allowance when determined to be no longer collectible. The Company regularly monitors and assesses its risk of not collecting amounts owed by customers and records its allowance for credit losses based on the results of this analysis. As of March 31, 2024 and December 31, 2023, we have reviewed the entire loan portfolio as well as all financial assets of the Company for the purpose of evaluating the loan portfolio and the loan balances, including a review of individual and collective portfolio loan quality, loan(s) performance, including past due status and covenant defaults, assessment of the ability of the borrower to repay the loan on the loan terms, whether any loans should be placed on nonaccrual or returned to accrual, any concentrations in any single borrower and/or industry that we might need to further manage, and if any specific or general loan loss reserve should be established for the entire loan portfolio or for any specific loan. We analyzed the loan loss reserve from three basis: general loan portfolio reserves; industry portfolio reserves, and specific loan loss reserves. For the three months ended March 31, 2024 and 2023, the Company recorded a Loan loss reserve of approximately $ 249,000 0 General Loan Portfolio Reserve - 249,000 194,000 Industry Portfolio Reserves - Specific Loan Reserves 884,000 2,884,000 1,045,000 475,000 135,000 158,000

Disposal of assets

Disposal of assets	3 Months Ended
	Mar. 31, 2024
Disposal Of Assets
Disposal of assets	7. Disposal of assets On July 1 st 1,000 706,000 758,000 698,000 59,000 the agreement includes payment of 1% royalty, starting November 1, 2023, being defined as 1% of the gross sale price of all Seller’s new products made and sold outside of existing inventory on the schedule, for a period ending October 31, 2033 639,000 On July 1 st 100 259,000 617,000

Investments

Investments	3 Months Ended
	Mar. 31, 2024
Investments, All Other Investments [Abstract]
Investments	8. Investments Alset International Limited related party The Company owns 127,179,291 4 2,353,000 3,269,000 916,000 1,156,000 West Park Capital, Inc. On December 30, 2020, the Company signed a binding letter of intent with West Park Capital, Inc (“West Park”) and TBD where the parties agreed to prepare a note and stock exchange agreement whereby DSS will assign the TBD Note to West Park and West Park shall issue to DSS a stock certificate reflecting 7.5 500,000 BMI Capital International LLC, related party On September 10, 2020, the Company’s wholly owned subsidiary DSS Securities, Inc. entered into membership interest purchase agreement with BMI Financial Group, Inc. a Delaware corporation (“BMIF”) and BMI Capital International LLC, a Texas limited liability company (“BMIC”) whereas DSS Securities, Inc. purchased 14.9 100,000 10 100,000 24.9 1,000 4,000 BMIC is a broker-dealer registered with the Securities and Exchange Commission, is a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”), and is a member of the Securities Investor Protection Corporation (“SIPC”). The Company’s chairman of the board and another independent board member of the Company also have ownership interest in BMIC. BioMed Technologies Asia Pacific Holdings Limited On December 19, 2020, Impact BioMedical, a wholly owned subsidiary of the Company, entered into a subscription agreement (the “Subscription Agreement”) with BioMed Technologies Asia Pacific Holdings Limited (“BioMed”), a limited liability company incorporated in the British Virgin Islands, pursuant to which the Company agreed to purchase 525 4.99 632,000 Under the terms of the Distribution Agreement, the Company will have exclusive rights to distribute the products within the United States, Canada, Singapore, Malaysia, and South Korea and non-exclusive distribution rights in all other countries. In exchange, the Company agreed to certain obligations, including mutual marketing obligations to promote sales of the products. This agreement is for ten years with a one year auto-renewal feature.

Short-Term and Long-Term Debt

Short-Term and Long-Term Debt	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Short-Term and Long-Term Debt	9. Short-Term and Long-Term Debt DSS, Inc Promissory Notes - 3,710,000 2,810,000 2,932,000 4.63 502,000 2,308,000 On August 1, 2021, AMRE Shelton, LLC., (“AMRE Shelton”) a subsidiary of AMRE, entered into a loan agreement (“Shelton Agreement”) with Patriot Bank, N.A. (“Patriot Bank”) in an amount up to $ 6,155,000 5,105,000 4.25 The interest will be adjusted commencing on July 1, 2026 and continuing for the next succeeding 5-year period shall be determined one month prior to the change date and shall be an interest rate equal to two hundred fifty (250) basis points above the Federal Home Loan Bank Boston 5-Year/25-Year amortizing advance rate, but in no event less than 4.25% for the term of 120 months 2,829,000 4.25 40,000 4,640,000 1,600,000 325,000 585,000 3 6,252,000 209,000 4,354,000 44,000 On October 13, 2021, LVAM entered into loan agreement with BMIC (“BMIC Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 October 12, 2022 512,000 547,000 On October 13, 2021, LVAM entered into a loan agreement with Lee Wilson Tsz Kin (“Wilson Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 October 12, 2022 1,143,000 2,131,000 On November 2, 2021, AMRE LifeCare entered into a loan agreement (“LifeCare Agreement”) with Pinnacle Bank, (“Pinnacle Bank”) in the amount of $ 40,300,000 62,000,000 32,100,000 12,100,000 1,500,000 15,901,000 1 11 41,570,000 The LifeCare Agreement calls for the principal amount of the in equal, consecutive monthly installments based upon a twenty-five (25) year amortization of the original principal amount of the LifeCare Agreement at an initial rate of interest equal to the interest rate determined in accordance as of July 29, 2022 provided, however, such rate of interest shall not be less than 4.28 9.6 41,331,000 42,308,000 977,000 850,000 On March 17, 2022, AMRE Winter Haven, LLC (“AMRE Winter Haven”) and Pinnacle Bank (“Pinnacle”) entered into a term loan (“Pinnacle Loan”) whereas Pinnacle lent to AMRE Winter Haven the principal sum of $ 2,990,000 March 7, 2024 4,500,000 3,200,000 1,000,000 222,000 29,000 5 4,380,000 25 4.28 17,000 2,977,000 2,987,000 38,000 23,000 On March 30, 2023, Premier Packaging, a subsidiary of the Company entered into a loan and security agreement with Union Bank & Trust Company for the principal amount of $ 790,000 7.44 14,000 691,000 116,000 575,000 719,000 112,000 607,000 13,000 0 A summary of scheduled principal payments of long-term debt, not including revolving lines of credit, subsequent to March 31, 2024, are as follows: Schedule of Notes Payable and Long-term Debt Year Amount 2024 $ 47,509,000 2025 858,000 2026 902,000 2027 948,000 2028 996,000 Thereafter 3,727,000

Lease Liability

Lease Liability	3 Months Ended
	Mar. 31, 2024
Lease Liability
Lease Liability	10. Lease Liability The Company has operating leases predominantly for operating facilities. As of March 31, 2024, the remaining lease terms on our operating leases range from less than one twelve years Future minimum lease payments as of March 31 2024, are as follows: Maturity of Lease Liability: Schedule of Future Minimum Lease Payments Totals 2024 $ 719,000 2025 861,000 2026 839,000 2027 808,000 2028 824,000 After 4,913,000 Total lease payments 8,964,000 Less: Imputed Interest (1,598,000 ) Present value of remaining lease payments $ 7,436,000 Current $ 684,000 Noncurrent $ 6,752,000 Weighted-average remaining lease term (years) 10.1 Weighted-average discount rate 4.1 % Total cash paid for leases during the three months ended March 31, 2024 and 2023 approximated $ 220,000 305,000

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies License Agreement In exchange, the Licensee shall pay the Company a royalty of 5.5% of net sales. Under the terms of the Equivir Agreement, the Company shall reimburse the Licensee for 50% of the development costs provided that the development costs shall not exceed $ 1,250,000 152,000 200,000

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Stockholders’ Equity	12. Stockholders’ Equity Equity transactions On April 10, 2023, the Company issued 1,247,078 268,000 On January 4, 2024 the Company effected a reverse stock split of 1 for 20 140,264,240 7,066,772 Stock-Based Compensation – The Company records stock-based payment expense related to options and warrants based on the grant date fair value in accordance with FASB ASC 718. Stock-based compensation includes expense charges for all stock-based awards to employees, directors, and consultants. Such awards include option grants, warrant grants, and restricted stock awards. During the three months ended March 31, 2024, there were none Impact BioMedical, Inc. Equity Transactions – On May 10, 2023, the Company, the Company’s Board of Directors approved an amendment to the Articles of Incorporation of the Company to increase the total number of shares of Common Stock to 4,000,000,000 shares with a par value of $0.001. Each share of Common Stock when issued, shall have one (1) vote on all matters presented to the stockholders. Our Amended and Restated Articles of Incorporation also authorized 100,000,000 shares of preferred stock, par value $0.001 per share. On May 11, 2023, the Company effected a forward split. As a result, there were 3,877,282,251 shares of our Common Stock and no shares of preferred stock issued and outstanding. Prior to the split, there were 125,073,621 shares of our Common Stock and no shares of preferred stock issued and outstanding. On October 31, 2023, the Company effected a reverse stock split of 1 for 55. Also on October 31, 2023, DSS BioHealth Securities, Inc., the Company’s largest shareholder converted 60,496,041 shares of Common Stock into 60,496,041 shares of Series A Convertible Preferred Shares, reducing its ownership of the Company’s Common Stock from approximately 88% to approximately 12%. As of March 31, 2024 and December 31, 2023, there were 10,000,000 shares of our Common Stock and 60,496,041 shares of preferred stock issued and outstanding On August 8, 2023 DSS, the Company’s largest shareholder, distributed to its shareholders of record on July 10, 2023 4 shares of Impact Bio’s stock for 1 share they owned. Each share of Impact BioMedical distributed as part of the distribution will not be eligible for resale until 180 days from the date Impact BioMedical’s initial public offering becomes effective under the Securities Act, subject to the discretion of the Company to lift the restriction sooner.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	3 Months Ended
	Mar. 31, 2024
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	13. Supplemental Cash Flow Information The following table summarizes supplemental cash flows for the three months ended March 31, 2024, and 2023: Schedule of Supplemental Cash Flow Information 2024 2023 Cash paid for interest $ 337,000 $ 249,000

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2024
Segment Reporting [Abstract]
Segment Information	14. Segment Information The Company’s nine businesses lines are organized, managed, and internally reported as five operating segments. One of these operating segments, Product Packaging, is the Company’s packaging and printing group. Product Packaging operates in the paper board folding carton, smart packaging, and document security printing markets. It markets, manufactures, and sells mailers, photo sleeves, sophisticated custom folding cartons, and complex 3-dimensional direct mail solutions. These products are designed to provide functionality and marketability while also providing counterfeit protection. A second, Biotechnology, invests in, or acquires companies in the biohealth and biomedical fields, including businesses focused on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. This division is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Biotechnology is also targeting unmet, urgent medical needs. A third operating segment, Securities, and Investment Management (“Securities”) was established to develop and/or acquire assets and investments in the securities trading and/or funds management arena. Further, Securities, in partnership with recognized global leaders in alternative trading systems, intends to own and operate in the US a single or multiple vertical digital asset exchanges for securities, tokenized assets, utility tokens, stable coins and cryptocurrency via a digital asset trading platform using blockchain technology. The scope of services within this section is planned to include asset issuance and allocation (securities and cryptocurrency), FPO, IPO, ITO, PPO, STO and UTO listings on a primary market(s), asset digitization/tokenization (securities, currency, and cryptocurrency), and the listing and trading of digital assets (securities and cryptocurrency) on a secondary market(s). Also in this segment is the Company’s real estate investment trust (“REIT”), organized for the purposes of acquiring hospitals and other acute or post-acute care centers from leading clinical operators with dominant market share in secondary and tertiary markets, and leasing each property to a single operator under a triple-net lease. the REIT was formed to originate, acquire, and lease a credit-centric portfolio of licensed medical real estate. The fourth segment, Direct, provides services to assist companies in the emerging growth gig business model of peer-to-peer decentralized sharing marketplaces. It specializes in marketing and licensing its products and services through its subsidiary and partner network, using the popular gig economic marketing strategy as a form of direct marketing. Direct marketing products include, among other things, nutritional and personal care products sold throughout North America, Asia Pacific and Eastern Europe (see Note 1, Deconsolidation of Sharing Services Global Corporation). The fifth business line, Commercial Banking, is organized for the purposes of being a financial network holding company, focused providing commercial loans and on acquiring equity positions in (i) undervalued commercial bank(s), bank holding companies and nonbanking licensed financial companies operating in the United States, South East Asia, Taiwan, Japan and South Korea, and (ii) companies engaged in—nonbanking activities closely related to banking, including loan syndication services, mortgage banking, trust and escrow services, banking technology, loan servicing, equipment leasing, problem asset management, SPAC (special purpose acquisition company) consulting, and advisory capital raising services. From this financial platform, the Company shall provide an integrated suite of financial services for businesses that shall include commercial business lines of credit, land development financing, inventory financing, third party loan servicing, and services that address the financial needs of the world Gig Economy. Approximate information concerning the Company’s operations by reportable segment for the three months ended March 31, 2024 and 2023 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein: Schedule of Operations by Reportable Segment Three Months Ended March 31, 2024 Product Packaging Commercial Lending Direct Marketing Biotechnology Securities Corporate Total Revenue $ 3,080,000 $ 104,000 $ - $ - $ 687,000 $ - $ 3,871,000 Depreciation and amortization 190,000 - 34,000 288,000 69,000 1,000 582,000 Cost of Revenue 2,767,000 469,000 - 10,000 1,744,000 - 4,990,000 Interest expense 47,000 - - - 1,099,000 - 1,146,000 Interest income - - 36,000 6,000 63,000 2,000 107,000 Net income (loss) from continuing operations (474,000 ) (1,382,000 ) (70,000 ) (942,000 ) (2,349,000 ) 108,000 (5,109,000 ) Capital expenditures 3,000 - - - - - 3,000 Total Identifiable assets 20,475,000 9,361,000 6,178,000 48,882,000 58,327,000 5,277,000 148,500,000 Assets held for sale - - - - 51,595,000 - 51,595,000 Three Months Ended March 31,2023 Product Packaging Commercial Lending Direct Marketing Biotechnology Securities Corporate Total Revenue $ 6,130,000 $ 117,000 $ 3,994,000 $ - $ 1,685,000 $ - $ 11,926,000 Depreciation and amortization 188,000 - 46,000 298,000 743,000 58,000 1,333,000 Cost of revenue 4,660,000 - 1,290,000 - 2,537,000 46,000 8,533,000 Interest expense 39,000 - - - 210,000 - 249,000 Interest income - - 4,000 94,000 32,000 - 130,000 Net income (loss) from continuing operations 696,000 (564,000 ) (3,187,000 ) (848,000 ) (2,028,000 ) (2,702,000 ) (8,633,000 ) Capital expenditures 576,000 - (15,000 ) 5,000 28,000 - 594,000 Identifiable assets 25,217,000 43,133,000 20,539,000 52,983,000 76,003,000 8,875,000 226,750,000 The following tables disaggregate our business segment revenues by major source: Printed Products Revenue Information: Schedule of Disaggregation of Revenue Three months ended March 31, 2024 Packaging Printing and Fabrication $ 2,882,000 Commercial and Security Printing 191,000 Total Printed Products $ 3,073,000 Three months ended March 31, 2023 Packaging Printing and Fabrication $ 5,865,000 Commercial and Security Printing 265,000 Total Printed Products $ 6,130,000 Direct Marketing Three months ended March 31, 2024 Direct Marketing Internet Sales $ - Total Direct Marketing $ - Three months ended March 31, 2023 Direct Marketing Internet Sales $ 3,994,000 Total Direct Marketing $ 3,994,000 Rental Income Three months ended March 31, 2024 Rental income $ 400,000 Total Rental Income $ 400,000 Three months ended March 31, 2023 Rental income $ 1,685,000 Total Rental Income $ 1,685,000 Commission Income Three months ended March 31, 2024 Commission income $ 303,000 Total commission income $ 303,000 Three months ended March 31, 2023 Commission income $ - Total commission income $ - Net Investment Income Three months ended March 31, 2024 Net investment income $ 95,000 Total Management fee income $ 95,000 Three months ended March 31, 2023 Net Investment Income $ 117,000 Total Management fee income $ 117,000

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2024
Related Party Transactions [Abstract]
Related Party Transactions	15. Related Party Transactions The Company owns 127,179,291 4 2,353,000 3,269,000 916,000 1,156,000 On September 10, 2020, the Company’s wholly owned subsidiary DSS Securities, Inc. entered into membership interest purchase agreement with BMI Financial Group, Inc. a Delaware corporation (“BMIF”) and BMI Capital International LLC, a Texas limited liability company (“BMIC”) whereas DSS Securities, Inc. purchased 14.9 100,000 10 100,000 24.9 1,000 4,000 On October 13, 2021, LVAM entered into loan agreement with BMIC (“BMIC Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 October 12, 2022 512,000 547,000 On October 13, 2021, LVAM entered into a loan agreement with Lee Wilson Tsz Kin (“Wilson Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 October 12, 2022 1,143,000 2,131,000 On August 29, 2022, DSS Financial Management Inc and Borrower 8, a related party, entered into a promissory note (“Note 8”) in the principal sum of $ 100,000 8 August 29, 2025 101,000 76,000 100,000 76,000 24,000 24.9 On May 8, 2023, DSS Financial Management Inc and Borrower 8 entered into a promissory note (“Note 9”) in the principal sum of $ 102,000 2 10.5 May 7, 2026 110,000 82,000 107,000 53,000 54,000 24.9 On July 26, 2022, APB and Borrower 10 entered into a promissory note (“Note 10”) in the principal sum of $ 1,000,000 8 July 26, 2024 940,000 10,000 475,000 939,000 20,000

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	16. Subsequent Events The Company has evaluated all subsequent events and transactions through May 14, 2024, the date that the condensed consolidated financial statements were available to be issued and noted no subsequent events requiring financial statement recognition or disclosure other than what was identified below:

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation
Deconsolidation of Sharing Services Global Corporation(“SHRG”)	Deconsolidation of Sharing Services Global Corporation(“SHRG”) 280 7 81 s a result, SHRG, whose operations represented a significant portion of our Direct Marketing segment, was deconsolidated from our consolidated financial statements effective as of May 1, 2023 (the “Deconsolidation”). The consolidated statement of operations for the fiscal quarter ended September 30, 2023, therefore includes one month of activity related to SHRG prior to the Deconsolidation. Subsequent to April 30, 2023 the assets and liabilities of SHRG are no longer included within our consolidated balance sheets. Any discussions related to results, operations, and accounting policies associated with SHRG refer to the periods prior to the Deconsolidation. Upon Deconsolidation, we recognized a loss before income taxes of approximately $ 29,196,000
Use of Estimates	Use of Estimates
Cash Equivalents	Cash Equivalents
Accounts/Rents Receivable	Accounts/Rents Receivable At March 31, 2024, and December 31, 2023, the Company established a reserve for credit losses of approximately $ 2,492,000 2,494,000
Concentration of Credit Risk	Concentration of Credit Risk - The Company maintains its cash in bank deposit accounts, which at times may exceed federally insured limits. The Company believes it is not exposed to any significant credit risk because of any non-performance by the financial institutions. As of March 31, 2024, one customers accounted for approximately 25 % of our consolidated revenue. As of March 31, 2024, one customers accounted for approximately 44 % of our trade accounts receivable balance. As of December 31, 2023, two customers accounted for approximately 20 % and 11 % of our consolidated revenue and 39 % and 30 % of our trade accounts receivable balance. As of March 31, 2024 and 2023, one vendor accounted for approximately 16 11
Notes receivable, unearned interest, and related recognition	Notes receivable, unearned interest, and related recognition
Allowance For Loans And Lease Losses	Allowance For Loans And Lease Losses ASU No.2016-13 – Credit Losses”
Investments	Investments
Fair Value of Financial Instruments	Fair Value of Financial Instruments - ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts reported in the consolidated balance sheet of cash and cash equivalents, accounts receivable, prepaids, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. Marketable securities classify as a Level 1 fair value financial instrument. The fair value of notes receivable approximates their carrying value as the stated or discounted rates of the notes do not reflect recent market conditions. The fair value of revolving credit lines notes payable and long-term debt approximates their carrying value as the stated or discounted rates of the debt reflect recent market conditions. The fair value of investments where the fair value is not considered readily determinable, are carried at cost.
Inventory	Inventory 15,000 18,000
Investments in real estate, net	Investments in real estate, net
Assets held for sale	Assets held for sale 5,593,000 41,570,000 4,396,000 65,000
Intangible Assets	Intangible Assets 7,418,000
Goodwill	Goodwill 1,769,000 25,093,000 29,744,000 1,234,000
Impairment of Long-Lived Assets and Goodwill	Impairment of Long-Lived Assets and Goodwill
Business Combinations	Business Combinations
Loss Per Common Share	Loss Per Common Share 5,000 0
Income Taxes	Income Taxes
Going Concern	Going Concern 9.3 Aside from its $ 9.3 8.5 723,000 51.6

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2024
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consisted of the following as of: Schedule of Inventory March December 2024 2023 Finished Goods $ 2,318,000 $ 2,218,000 Work in Process 845,000 180,000 Raw Materials 479,000 439,000 Inventory Gross $ 3,642,000 $ 2,837,000 Less allowance for obsolescence (15,000 ) (18,000 ) Inventory Net $ 3,627,000 $ 2,819,000

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2024
Investments, All Other Investments [Abstract]
Schedule of Cash and Marketable Securities by Significant Investment Category	The following tables show the Company’s cash, cash equivalents, restricted cash, and marketable securities by significant investment category as of March 31, 2024 and December 31, 2023: Schedule of Cash and Marketable Securities by Significant Investment Category 2024 cost Unrealized Gain/(Loss) Fair Value Cash and Cash Equivalents Marketable Securities Cash $ 9,182,000 $ - $ 9,182,000 $ 9,182,000 $ - Level 1 Money Market Funds 70,000 - 70,000 70,000 - Marketable Securities 26,629,000 (17,146,000 ) 8,483,000 - 8,483,000 Total $ 34,881,000 $ (17,146,000 ) $ 17,735,000 $ 9,252,000 $ 8,483,000 2023 Adjusted Cost Unrealized Gain/(Loss) Fair Value Cash and Cash Equivalents Marketable Securities Cash $ 6,545,000 $ - $ 6,545,000 $ 6,545,000 $ - Level 1 Money Market Funds $ 70,000 - $ 70,000 70,000 - Marketable Securities $ 27,304,000 (17,325,000 ) $ 9,979,000 - 9,979,000 Total $ 33,919,000 $ (17,325,000 ) $ 16,594,000 $ 6,615,000 $ 9,979,000

Short-Term and Long-Term Debt (

Short-Term and Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Schedule of Notes Payable and Long-term Debt	A summary of scheduled principal payments of long-term debt, not including revolving lines of credit, subsequent to March 31, 2024, are as follows: Schedule of Notes Payable and Long-term Debt Year Amount 2024 $ 47,509,000 2025 858,000 2026 902,000 2027 948,000 2028 996,000 Thereafter 3,727,000

Lease Liability (Tables)

Lease Liability (Tables)	3 Months Ended
	Mar. 31, 2024
Lease Liability
Schedule of Future Minimum Lease Payments	Future minimum lease payments as of March 31 2024, are as follows: Maturity of Lease Liability: Schedule of Future Minimum Lease Payments Totals 2024 $ 719,000 2025 861,000 2026 839,000 2027 808,000 2028 824,000 After 4,913,000 Total lease payments 8,964,000 Less: Imputed Interest (1,598,000 ) Present value of remaining lease payments $ 7,436,000 Current $ 684,000 Noncurrent $ 6,752,000 Weighted-average remaining lease term (years) 10.1 Weighted-average discount rate 4.1 %

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	3 Months Ended
	Mar. 31, 2024
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplemental Cash Flow Information	The following table summarizes supplemental cash flows for the three months ended March 31, 2024, and 2023: Schedule of Supplemental Cash Flow Information 2024 2023 Cash paid for interest $ 337,000 $ 249,000

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2024
Segment Reporting [Abstract]
Schedule of Operations by Reportable Segment	Approximate information concerning the Company’s operations by reportable segment for the three months ended March 31, 2024 and 2023 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein: Schedule of Operations by Reportable Segment Three Months Ended March 31, 2024 Product Packaging Commercial Lending Direct Marketing Biotechnology Securities Corporate Total Revenue $ 3,080,000 $ 104,000 $ - $ - $ 687,000 $ - $ 3,871,000 Depreciation and amortization 190,000 - 34,000 288,000 69,000 1,000 582,000 Cost of Revenue 2,767,000 469,000 - 10,000 1,744,000 - 4,990,000 Interest expense 47,000 - - - 1,099,000 - 1,146,000 Interest income - - 36,000 6,000 63,000 2,000 107,000 Net income (loss) from continuing operations (474,000 ) (1,382,000 ) (70,000 ) (942,000 ) (2,349,000 ) 108,000 (5,109,000 ) Capital expenditures 3,000 - - - - - 3,000 Total Identifiable assets 20,475,000 9,361,000 6,178,000 48,882,000 58,327,000 5,277,000 148,500,000 Assets held for sale - - - - 51,595,000 - 51,595,000 Three Months Ended March 31,2023 Product Packaging Commercial Lending Direct Marketing Biotechnology Securities Corporate Total Revenue $ 6,130,000 $ 117,000 $ 3,994,000 $ - $ 1,685,000 $ - $ 11,926,000 Depreciation and amortization 188,000 - 46,000 298,000 743,000 58,000 1,333,000 Cost of revenue 4,660,000 - 1,290,000 - 2,537,000 46,000 8,533,000 Interest expense 39,000 - - - 210,000 - 249,000 Interest income - - 4,000 94,000 32,000 - 130,000 Net income (loss) from continuing operations 696,000 (564,000 ) (3,187,000 ) (848,000 ) (2,028,000 ) (2,702,000 ) (8,633,000 ) Capital expenditures 576,000 - (15,000 ) 5,000 28,000 - 594,000 Identifiable assets 25,217,000 43,133,000 20,539,000 52,983,000 76,003,000 8,875,000 226,750,000
Schedule of Disaggregation of Revenue	The following tables disaggregate our business segment revenues by major source: Printed Products Revenue Information: Schedule of Disaggregation of Revenue Three months ended March 31, 2024 Packaging Printing and Fabrication $ 2,882,000 Commercial and Security Printing 191,000 Total Printed Products $ 3,073,000 Three months ended March 31, 2023 Packaging Printing and Fabrication $ 5,865,000 Commercial and Security Printing 265,000 Total Printed Products $ 6,130,000 Direct Marketing Three months ended March 31, 2024 Direct Marketing Internet Sales $ - Total Direct Marketing $ - Three months ended March 31, 2023 Direct Marketing Internet Sales $ 3,994,000 Total Direct Marketing $ 3,994,000 Rental Income Three months ended March 31, 2024 Rental income $ 400,000 Total Rental Income $ 400,000 Three months ended March 31, 2023 Rental income $ 1,685,000 Total Rental Income $ 1,685,000 Commission Income Three months ended March 31, 2024 Commission income $ 303,000 Total commission income $ 303,000 Three months ended March 31, 2023 Commission income $ - Total commission income $ - Net Investment Income Three months ended March 31, 2024 Net investment income $ 95,000 Total Management fee income $ 95,000 Three months ended March 31, 2023 Net Investment Income $ 117,000 Total Management fee income $ 117,000

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Details Narrative) - USD ($)		3 Months Ended		12 Months Ended
	May 04, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Deconsolidation on loss before income taxes	$ 29,196,000
Reserve for doubtful accounts		$ 2,492,000		$ 2,494,000
Inventory Adjustments		15,000		18,000
Other assets		65,000
Asset impairment				7,418,000
Goodwill		26,862,000		26,862,000
Cash		9,300,000
Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale		8,500,000
Principal and interest on note receivable		723,000
Assets held for sale		$ 51,624,000		51,595,000
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		0	5,000
AMRE Life Care Portfolio LLC [Member]
Real Estate Assets Held for Development and Sale		$ 41,570,000
AMRE Winter Haven LLC [Member]
Real Estate Assets Held for Development and Sale		4,396,000
Premier Packaging Corp [Member]
Goodwill		1,769,000
Impact BioMedical, Inc. [Member]
Goodwill		25,093,000
American Pacific Bancorp [Member]
Goodwill				29,744,000
Sentinel Brokers Company Inc [Member]
Goodwill				1,234,000
UTAH
Real Estate Assets Held for Development and Sale		5,593,000
Premier Subsidiary [Member]
Inventory Adjustments		$ 15,000		$ 18,000
Customer One [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Concentration Risk, Percentage		25%		20%
Customer One [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Concentration Risk, Percentage		44%		39%
Customer Two [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Concentration Risk, Percentage				11%
Customer Two [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Concentration Risk, Percentage				30%
Vendor One [Member] | Cost of Goods and Service, Product and Service Benchmark [Member] | Customer Concentration Risk [Member]
Concentration Risk, Percentage		16%	11%
Sharing Services Global Corp [Member]
Number of shares issued	280,000,000
Ownership interest percentage	7%
Percentage of issued and outstanding	81%

Schedule of Inventory (Details)

Schedule of Inventory (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Finished Goods	$ 2,318,000	$ 2,218,000
Work in Process	845,000	180,000
Raw Materials	479,000	439,000
Inventory Gross	3,642,000	2,837,000
Less allowance for obsolescence	(15,000)	(18,000)
Inventory Net	$ 3,627,000	$ 2,819,000

Notes Receivable (Details Narra

Notes Receivable (Details Narrative) - USD ($)

3 Months Ended

12 Months Ended

Jun. 27, 2023

May 08, 2023

Mar. 31, 2023

Dec. 29, 2022

Aug. 29, 2022

Jul. 26, 2022

May 09, 2022

Mar. 02, 2022

Jan. 24, 2022

Dec. 28, 2021

Oct. 25, 2021

May 14, 2021

Feb. 19, 2021

Mar. 31, 2024

Dec. 31, 2023

Nov. 27, 2023

Dec. 31, 2022

Sep. 23, 2021

Financing Receivable, Modified [Line Items]

Notes receivable current

$ 4,062,000

$ 8,772,000

Long term portion of notes receivable

87,000

111,000

Long term debt current

47,509,000

47,776,000

Long term debt

7,431,000

7,451,000

Note 1 [Member]

Financing Receivable, Modified [Line Items]

Debt instrument face amount

$ 5,000,000

Debt instrument interest rate

6.65%

Debt conversion description

Note 1 contains an optional conversion clause that allows the Company to convert all, or a portion of all, into newly issued member units of Borrower 1 with the maximum principal amount equal to 18% of the total equity position of Borrower 1 at conversion

Notes receivable current

5,544,000

5,544,000

Reserve amount

2,772,000

2,772,000

Note 2 [Member]

Financing Receivable, Modified [Line Items]

Debt instrument face amount

$ 3,500,000

Debt instrument interest rate

5.59%

Notes receivable current

3,910,000

Note 3 [Member]

Financing Receivable, Modified [Line Items]

Debt instrument interest rate

8%

Notes receivable current

$ 884,000

Line of credit facility, maximum borrowing capacity

$ 3,000,000

Debt instrument maturity date

Oct. 25, 2022

Note 3 [Member] | Maximum [Member]

Financing Receivable, Modified [Line Items]

Debt instrument face amount

$ 1,000,000

Note 4 [Member]

Financing Receivable, Modified [Line Items]

Debt instrument face amount

$ 700,000

Debt instrument interest rate

12%

Notes receivable current

158,000

253,000

$ 50,000

Debt instrument maturity date

Dec. 28, 2022

Extended maturity date

May 31, 2023

Note 5 [Member]

Financing Receivable, Modified [Line Items]

Debt instrument face amount

$ 100,000

Debt instrument interest rate

6%

Debt instrument, face amount

January 2024

Long term portion of notes receivable

107,000

103,000

Note 6 [Member]

Financing Receivable, Modified [Line Items]

Debt instrument face amount

$ 893,000

Debt instrument interest rate

8%

Debt instrument, face amount

March 2024

Notes and loans receivable gross current

458,000

446,000

Unamortized origination fees

3,500

3,500

Note 7 [Member]

Financing Receivable, Modified [Line Items]

Debt instrument face amount

$ 210,000

Debt instrument interest rate

10%

Notes receivable current

224,000

Debt instrument maturity date

Feb. 09, 2023

Notes receivable current reserved

112,000

Note 8 [Member]

Financing Receivable, Modified [Line Items]

Debt instrument face amount

$ 100,000

Debt instrument interest rate

8%

Notes receivable current

76,000

76,000

Debt instrument maturity date

Aug. 29, 2025

Long term portion of notes receivable

24,000

Notes and loans receivable gross current

$ 101,000

100,000

Note 8 [Member] | DSS Financial Management Inc [Member]

Financing Receivable, Modified [Line Items]

Ownership percentage

24.90%

Note 9 [Member]

Financing Receivable, Modified [Line Items]

Debt instrument face amount

$ 102,000

Debt instrument interest rate

2%

24.90%

Notes receivable current

$ 82,000

54,000

Debt instrument maturity date

May 07, 2026

Notes and loans receivable gross current

$ 110,000

$ 107,000

Effective rate percentage

10.50%

10.50%

Long term debt current

$ 82,000

$ 53,000

Long term debt

28,000

Long term debt

$ 54,000

Note 9 [Member] | DSS Financial Management Inc [Member]

Financing Receivable, Modified [Line Items]

Ownership percentage

24.90%

Note 10 [Member]

Financing Receivable, Modified [Line Items]

Debt instrument face amount

$ 1,000,000

$ 949,000

Debt instrument interest rate

8%

Notes receivable current

475,000

Debt instrument maturity date

Jul. 26, 2024

Notes and loans receivable gross current

940,000

939,000

Unamortized origination fees

10,000

20,000

Unamortized origination fees

475,000

Note 11 [Member]

Financing Receivable, Modified [Line Items]

Debt instrument face amount

$ 206,000

Debt instrument interest rate

6.50%

Debt instrument maturity date

Aug. 19, 2022

Notes and loans receivable gross current

$ 203,000

Note 12 [Member]

Financing Receivable, Modified [Line Items]

Debt instrument face amount

$ 1,400,000

Debt instrument interest rate

10%

Debt instrument maturity date

Sep. 01, 2024

Debt instrument, unamortized discount

$ 300,000

Note 13 [Member]

Financing Receivable, Modified [Line Items]

Debt instrument face amount

$ 140,000

Debt instrument interest rate

8.50%

8.50%

Debt instrument maturity date

Mar. 31, 2025

Notes and loans receivable gross current

$ 135,000

$ 133,000

Long term debt current

99,000

Long term debt

$ 34,000

Schedule of Cash and Marketable

Schedule of Cash and Marketable Securities by Significant Investment Category (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Cash and Cash Equivalents [Line Items]
Cost	$ 34,881,000	$ 33,919,000
Unrealized Gain/(Loss)	(17,146,000)	(17,325,000)
Fair Value	17,735,000	16,594,000
Cash and Cash Equivalents	9,252,000	6,615,000
Current marketable securities	8,483,000	9,979,000
Cash [Member]
Cash and Cash Equivalents [Line Items]
Cost	9,182,000	6,545,000
Unrealized Gain/(Loss)
Fair Value	9,182,000	6,545,000
Cash and Cash Equivalents	9,182,000	6,545,000
Current marketable securities
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents [Line Items]
Cost	70,000	70,000
Unrealized Gain/(Loss)
Fair Value	70,000	70,000
Cash and Cash Equivalents	70,000	70,000
Current marketable securities
Marketable Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents [Line Items]
Cost	26,629,000	27,304,000
Unrealized Gain/(Loss)	(17,146,000)	(17,325,000)
Fair Value	8,483,000	9,979,000
Cash and Cash Equivalents
Current marketable securities	$ 8,483,000	$ 9,979,000

Provision for Credit Losses (De

Provision for Credit Losses (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
General Loan Portfolio Reserve [Member] | American Pacific Bancorp [Member]
Financing Receivable, Past Due [Line Items]
Portfolio reserve	$ 249,000		$ 194,000
Specific Loan Reserves [Member] | Borrower 3 [Member]
Financing Receivable, Past Due [Line Items]
Current nonaccrual loan balance	884,000		884,000
Specific Loan Reserves [Member] | Borrower One [Member]
Financing Receivable, Past Due [Line Items]
Outstanding principal and interest	2,884,000		2,884,000
Specific Loan Reserves [Member] | Borrower Twelve [Member]
Financing Receivable, Past Due [Line Items]
Outstanding principal and interest	1,045,000		$ 1,045,000
Specific Loan Reserves [Member] | Borrower Ten [Member]
Financing Receivable, Past Due [Line Items]
Outstanding principal and interest	475,000
Specific Loan Reserves [Member] | Borrower 13 [Member]
Financing Receivable, Past Due [Line Items]
Outstanding principal and interest	135,000
Specific Loan Reserves [Member] | Borrower 8 [Member]
Financing Receivable, Past Due [Line Items]
Outstanding principal and interest	158,000
Loan [Member]
Financing Receivable, Past Due [Line Items]
Portfolio reserve	$ 249,000	$ 0

Disposal of assets (Details Nar

Disposal of assets (Details Narrative) - USD ($)		3 Months Ended
	Jul. 01, 2023	Mar. 31, 2024	Mar. 31, 2023
Net loss		$ (4,072,000)	$ (8,035,000)
HWH World Inc [Member]
Equity percentage	100%
Sharing Services Global Corporation [Member] | Amended Agreement [Member]
Purchase price to be paid	$ 758,000
Proceeds from sale of inventory	698,000
Liabilities assumed	59,000
Agreement description		the agreement includes payment of 1% royalty, starting November 1, 2023, being defined as 1% of the gross sale price of all Seller’s new products made and sold outside of existing inventory on the schedule, for a period ending October 31, 2033
Net loss		$ 639,000
HWH World Inc [Member]
Net loss	617,000
Purchase price consideration	$ 259,000
HWH World Inc [Member] | Sharing Services Global Corporation [Member]
Sale of stock, number of shares issued in transaction	1,000
Sale of stock, consideration received per transaction	$ 706,000

Investments (Details Narrative)

Investments (Details Narrative) - USD ($)				3 Months Ended		12 Months Ended
	Dec. 30, 2020	Dec. 19, 2020	Sep. 10, 2020	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Unrealized gain loss on investments				$ (17,146,000)		$ (17,325,000)
Net loss				(4,072,000)	$ (8,035,000)
BMI Capital International LLC [Member]
Issuance of common stock, net of expenses			$ 100,000
Net loss				$ 1,000	4,000
DSS Securities, Inc. [Member]
Equity method investment ownership percentage			14.90%
BMI Capital International LLC [Member]
Equity method investment ownership percentage			24.90%
BioMed Technologies Asia Pacific Holdings Limited [Member]
Equity method investment ownership percentage		4.99%
Issuance of common stock, net of expenses		$ 632,000
Issuance of common stock, net of expenses, shares		525
Alset International Limited [Member]
Owners shares				127,179,291
Outstanding share percentage				4%
Marketable securities				$ 2,353,000		3,269,000
Unrealized gain loss on investments				916,000	$ 1,156,000
West Park Capital, Inc [Member]
Debt instrument convertible threshold percentage of stock price trigger	7.50%
Investments				$ 500,000		$ 500,000
DSS Securities, Inc. [Member]
Issuance of common stock, net of expenses			$ 100,000
Outstanding membership interest			10%

Schedule of Notes Payable and L

Schedule of Notes Payable and Long-term Debt (Details)	Mar. 31, 2024 USD ($)
Debt Disclosure [Abstract]
2024	$ 47,509,000
2025	858,000
2026	902,000
2027	948,000
2028	996,000
Thereafter	$ 3,727,000

Short-Term and Long-Term Debt_2

Short-Term and Long-Term Debt (Details Narrative)						3 Months Ended
	Mar. 30, 2023 USD ($)	Mar. 17, 2022 USD ($)	Nov. 02, 2021 USD ($)	Oct. 13, 2021 USD ($)	Aug. 01, 2021 USD ($) ft²	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022	Jul. 29, 2022	May 20, 2021 USD ($)
Debt Instrument [Line Items]
Long term debt current						$ 47,509,000		$ 47,776,000
Payments to acquire assets						3,000	$ 594,000
Net book value of assets						6,225,000		6,417,000
Interest expense						48,000	249,000
Pinnacle Loan [Member]
Debt Instrument [Line Items]
Debt instrument, face amount		$ 2,990,000				2,987,000		17,000
Principal interest percentage		4.28%
Payments to intangible assets		$ 29,000
Estimated useful life		5 years
Net book value of assets						4,380,000
Debt issuance costs								2,977,000
Maturity date		Mar. 07, 2024
Purchase price		$ 4,500,000
Interest expense						38,000	23,000
Debt instrument term		25 years
Facility [Member] | Pinnacle Loan [Member]
Debt Instrument [Line Items]
Payments to acquire assets		$ 3,200,000
Land [Member] | Pinnacle Loan [Member]
Debt Instrument [Line Items]
Payments to acquire assets		1,000,000
Site and Tenant Improvements [Member] | Pinnacle Loan [Member]
Debt Instrument [Line Items]
Payments to acquire assets		$ 222,000
BMIC Loan [Member]
Debt Instrument [Line Items]
Debt instrument, face amount				$ 3,000,000		512,000		547,000
Maturity date				Oct. 12, 2022
Wilson Loan [Member]
Debt Instrument [Line Items]
Debt instrument, face amount				$ 3,000,000		1,143,000		2,131,000
Maturity date				Oct. 12, 2022
Security Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 790,000					691,000		719,000
Long term debt current						116,000		112,000
Long term debt						575,000		607,000
Interest expense						13,000	0
Interest expense debt	$ 14,000
Premier Packaging Bank Of America NA [Member]
Debt Instrument [Line Items]
Debt financing amount											$ 3,710,000
Debt instrument, face amount						2,810,000		2,932,000
Principal interest percentage											4.63%
Long term debt current						502,000
Long term debt						2,308,000
AMRE Shelton LLC [Member] | Loan Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, face amount					$ 6,155,000
Principal interest percentage					4.25%
Long term debt current					$ 5,105,000	209,000
Long term debt						4,354,000
Debt instrument description					The interest will be adjusted commencing on July 1, 2026 and continuing for the next succeeding 5-year period shall be determined one month prior to the change date and shall be an interest rate equal to two hundred fifty (250) basis points above the Federal Home Loan Bank Boston 5-Year/25-Year amortizing advance rate, but in no event less than 4.25% for the term of 120 months
Debt instrument periodic payment					$ 2,829,000
Debt effective interest rate percentage									4.25%
Area of land | ft²					40,000
Payments to intangible assets					$ 585,000
Net book value of assets						6,252,000
Debt issuance costs						44,000
AMRE Shelton LLC [Member] | Loan Agreement [Member] | Facility [Member]
Debt Instrument [Line Items]
Payments to acquire assets					4,640,000
AMRE Shelton LLC [Member] | Loan Agreement [Member] | Land [Member]
Debt Instrument [Line Items]
Payments to acquire assets					1,600,000
AMRE Shelton LLC [Member] | Loan Agreement [Member] | Tenant Improvements [Member]
Debt Instrument [Line Items]
Payments to acquire assets					$ 325,000
AMRE Shelton LLC [Member] | Loan Agreement [Member] | Other Intangible Assets [Member]
Debt Instrument [Line Items]
Estimated useful life					3 years
Pinnacle Bank [Member] | LifeCare Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, face amount			$ 40,300,000			$ 42,308,000		$ 41,331,000
Debt instrument description			The LifeCare Agreement calls for the principal amount of the in equal, consecutive monthly installments based upon a twenty-five (25) year amortization of the original principal amount of the LifeCare Agreement at an initial rate of interest equal to the interest rate determined in accordance as of July 29, 2022 provided, however, such rate of interest shall not be less than 4.28%, with the first such installment being payable on August 29, 2022 and subsequent installments being payable on the first day of each succeeding month thereafter until the maturity date, at which time any outstanding principal and interest is due in full.
Debt effective interest rate percentage						9.60%				4.28%
Payments to intangible assets			$ 15,901,000
Net book value of assets						$ 41,570,000
Purchase price			$ 62,000,000
Interest expense						$ 977,000	$ 850,000
Pinnacle Bank [Member] | LifeCare Agreement [Member] | Minimum [Member]
Debt Instrument [Line Items]
Estimated useful life			1 year
Pinnacle Bank [Member] | LifeCare Agreement [Member] | Maximum [Member]
Debt Instrument [Line Items]
Estimated useful life			11 years
Pinnacle Bank [Member] | LifeCare Agreement [Member] | Facility [Member]
Debt Instrument [Line Items]
Payments to acquire assets			$ 32,100,000
Pinnacle Bank [Member] | LifeCare Agreement [Member] | Land [Member]
Debt Instrument [Line Items]
Payments to acquire assets			12,100,000
Pinnacle Bank [Member] | LifeCare Agreement [Member] | Site Improvements [Member]
Debt Instrument [Line Items]
Payments to acquire assets			$ 1,500,000
Union Bank And Trust Company [Member] | Security Agreement [Member]
Debt Instrument [Line Items]
Principal interest percentage	7.44%

Schedule of Future Minimum Leas

Schedule of Future Minimum Lease Payments (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Lease Liability
2024	$ 719,000
2025	861,000
2026	839,000
2027	808,000
2028	824,000
After	4,913,000
Total lease payments	8,964,000
Less: Imputed Interest	(1,598,000)
Present value of remaining lease payments	7,436,000
Current	684,000	$ 686,000
Noncurrent	$ 6,752,000	$ 6,917,000
Weighted-average remaining lease term (years)	10 years 1 month 6 days
Weighted-average discount rate	4.10%

Lease Liability (Details Narrat

Lease Liability (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash paid for leases	$ 220,000	$ 305,000
Minimum [Member]
Remaining lease term	1 year
Maximum [Member]
Remaining lease term	12 years

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - License Agreement [Member] - USD ($)	Mar. 19, 2022	Mar. 19, 2022	Mar. 31, 2024	Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Development costs	$ 1,250,000
Equivir License [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accrued expense			$ 152,000	$ 200,000
Bio Medical [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Loss contingency allegations		In exchange, the Licensee shall pay the Company a royalty of 5.5% of net sales. Under the terms of the Equivir Agreement, the Company shall reimburse the Licensee for 50% of the development costs provided that the development costs shall not exceed $1,250,000. As of March 31, 2024 and December 31, 2023, $152,000 and $200,000, respectively, has been accrued for in relation to the Equivir License as development of the Equivir technology.

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)				3 Months Ended	12 Months Ended
	Jan. 04, 2024	May 10, 2023	Apr. 10, 2023	Mar. 31, 2024	Dec. 31, 2023
Class of Stock [Line Items]
Stockholders' equity, reverse stock split	1 for 20
Common stock shares issued				7,066,772	7,066,772
Common stock shares outstanding				7,066,772	7,066,772
Share based compensation expense				$ 0
Stockholders' Equity Note, Stock Split		On May 10, 2023, the Company, the Company’s Board of Directors approved an amendment to the Articles of Incorporation of the Company to increase the total number of shares of Common Stock to 4,000,000,000 shares with a par value of $0.001. Each share of Common Stock when issued, shall have one (1) vote on all matters presented to the stockholders. Our Amended and Restated Articles of Incorporation also authorized 100,000,000 shares of preferred stock, par value $0.001 per share. On May 11, 2023, the Company effected a forward split. As a result, there were 3,877,282,251 shares of our Common Stock and no shares of preferred stock issued and outstanding. Prior to the split, there were 125,073,621 shares of our Common Stock and no shares of preferred stock issued and outstanding. On October 31, 2023, the Company effected a reverse stock split of 1 for 55. Also on October 31, 2023, DSS BioHealth Securities, Inc., the Company’s largest shareholder converted 60,496,041 shares of Common Stock into 60,496,041 shares of Series A Convertible Preferred Shares, reducing its ownership of the Company’s Common Stock from approximately 88% to approximately 12%. As of March 31, 2024 and December 31, 2023, there were 10,000,000 shares of our Common Stock and 60,496,041 shares of preferred stock issued and outstanding
Convertible Common Stock [Member]
Class of Stock [Line Items]
Common stock shares issued					140,264,240
Common stock shares outstanding					140,264,240
Conversion of stock, shares converted					7,066,772
Frank Heuszel [Member] | Employment Agreement [Member]
Class of Stock [Line Items]
Number of shares of common stock			1,247,078
Number of shares of common stock, values			$ 268,000

Schedule of Supplemental Cash F

Schedule of Supplemental Cash Flow Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Supplemental Cash Flow Elements [Abstract]
Cash paid for interest	$ 337,000	$ 249,000

Schedule of Operations by Repor

Schedule of Operations by Reportable Segment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Segment Reporting Information [Line Items]
Revenue	$ 3,871,000	$ 11,926,000
Depreciation and amortization	582,000	1,333,000
Interest expense	48,000	249,000
Interest income	107,000	130,000
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	3,871,000	11,926,000
Depreciation and amortization	582,000	1,333,000
Cost of revenue	4,990,000	8,533,000
Interest expense	1,146,000	249,000
Interest income	107,000	130,000
Net income (loss) from continuing operations	(5,109,000)	(8,633,000)
Capital expenditures	3,000	594,000
Identifiable assets	148,500,000	226,750,000
Assets held for sale	51,595,000
Operating Segments [Member] | Product Packaging [Member]
Segment Reporting Information [Line Items]
Revenue	3,080,000	6,130,000
Depreciation and amortization	190,000	188,000
Cost of revenue	2,767,000	4,660,000
Interest expense	47,000	39,000
Interest income
Net income (loss) from continuing operations	(474,000)	696,000
Capital expenditures	3,000	576,000
Identifiable assets	20,475,000	25,217,000
Assets held for sale
Operating Segments [Member] | Commercial Banking [Member]
Segment Reporting Information [Line Items]
Revenue	104,000	117,000
Depreciation and amortization
Cost of revenue	469,000
Interest expense
Interest income
Net income (loss) from continuing operations	(1,382,000)	(564,000)
Capital expenditures
Identifiable assets	9,361,000	43,133,000
Assets held for sale
Operating Segments [Member] | Direct Marketing Online Sales [Member]
Segment Reporting Information [Line Items]
Revenue		3,994,000
Depreciation and amortization	34,000	46,000
Cost of revenue		1,290,000
Interest expense
Interest income	36,000	4,000
Net income (loss) from continuing operations	(70,000)	(3,187,000)
Capital expenditures		(15,000)
Identifiable assets	6,178,000	20,539,000
Assets held for sale
Operating Segments [Member] | Biotechnology [Member]
Segment Reporting Information [Line Items]
Revenue
Depreciation and amortization	288,000	298,000
Cost of revenue	10,000
Interest expense
Interest income	6,000	94,000
Net income (loss) from continuing operations	(942,000)	(848,000)
Capital expenditures		5,000
Identifiable assets	48,882,000	52,983,000
Assets held for sale
Operating Segments [Member] | Securities [Member]
Segment Reporting Information [Line Items]
Revenue	687,000	1,685,000
Depreciation and amortization	69,000	743,000
Cost of revenue	1,744,000	2,537,000
Interest expense	1,099,000	210,000
Interest income	63,000	32,000
Net income (loss) from continuing operations	(2,349,000)	(2,028,000)
Capital expenditures		28,000
Identifiable assets	58,327,000	76,003,000
Assets held for sale	51,595,000
Operating Segments [Member] | Corporate Segment [Member]
Segment Reporting Information [Line Items]
Revenue
Depreciation and amortization	1,000	58,000
Cost of revenue		46,000
Interest expense
Interest income	2,000
Net income (loss) from continuing operations	108,000	(2,702,000)
Capital expenditures
Identifiable assets	5,277,000	$ 8,875,000
Assets held for sale

Schedule of Disaggregation of R

Schedule of Disaggregation of Revenue (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Segment Reporting Information [Line Items]
Revenue	$ 3,871,000	$ 11,926,000
Printed Products [Member]
Segment Reporting Information [Line Items]
Revenue	3,073,000	6,130,000
Direct Marketing [Member]
Segment Reporting Information [Line Items]
Revenue		3,994,000
Rental Revenue Income [Member]
Segment Reporting Information [Line Items]
Revenue	400,000	1,685,000
Commission Revenue [Member]
Segment Reporting Information [Line Items]
Revenue	303,000
Net Investment Revenue Income [Member]
Segment Reporting Information [Line Items]
Revenue	95,000	117,000
Packaging Printing and Fabrication [Member] | Printed Products [Member]
Segment Reporting Information [Line Items]
Revenue	2,882,000	5,865,000
Commercial and Security Printing [Member] | Printed Products [Member]
Segment Reporting Information [Line Items]
Revenue	191,000	265,000
Direct Marketing Internet Sales [Member] | Direct Marketing [Member]
Segment Reporting Information [Line Items]
Revenue		3,994,000
Rental Income [Member] | Rental Revenue Income [Member]
Segment Reporting Information [Line Items]
Revenue	400,000	1,685,000
Commission Income [Member] | Commission Revenue [Member]
Segment Reporting Information [Line Items]
Revenue	303,000
Net Investment Income [Member] | Net Investment Revenue Income [Member]
Segment Reporting Information [Line Items]
Revenue	$ 95,000	$ 117,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)						3 Months Ended		12 Months Ended
	May 08, 2023	Aug. 29, 2022	Jul. 26, 2022	Oct. 13, 2021	Sep. 10, 2020	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Unrealized loss on investment						$ (17,146,000)		$ (17,325,000)
Net loss						(4,072,000)	$ (8,035,000)
Notes receivable current						4,062,000		8,772,000
Long term portion of notes receivable						87,000		111,000
Principal and accrued interest						47,509,000		47,776,000
Note 8 [Member]
Principal amount		$ 100,000
Maturity date		Aug. 29, 2025
Debt instrument interest percentage		8%
Notes and loans receivable gross current						101,000		100,000
Notes receivable current						$ 76,000		76,000
Long term portion of notes receivable								24,000
Note 9 [Member]
Principal amount	$ 102,000
Maturity date	May 07, 2026
Debt instrument interest percentage	2%					24.90%
Notes and loans receivable gross current						$ 110,000		107,000
Notes receivable current						$ 82,000		$ 54,000
Effective rate percentage						10.50%		10.50%
Principal and accrued interest						$ 82,000		$ 53,000
Note 10 [Member]
Principal amount			$ 1,000,000			949,000
Maturity date			Jul. 26, 2024
Debt instrument interest percentage			8%
Notes and loans receivable gross current						940,000		939,000
Notes receivable current						475,000
Unamortized origination fees						10,000		20,000
BMIC Loan [Member]
Principal amount				$ 3,000,000		512,000		547,000
Maturity date				Oct. 12, 2022
Wilson Loan [Member]
Principal amount				$ 3,000,000		1,143,000		2,131,000
Maturity date				Oct. 12, 2022
BMI Capital International LLC [Member]
Issuance of common stock, net of expenses					$ 100,000
Net loss						$ 1,000	4,000
DSS Securities, Inc. [Member]
Ownership percentage					14.90%
BMI Capital International LLC [Member]
Ownership percentage					24.90%
DSS Financial Management Inc [Member] | Note 8 [Member]
Ownership percentage						24.90%
DSS Financial Management Inc [Member] | Note 9 [Member]
Ownership percentage						24.90%
Alset International Limited [Member]
Investment owned, balance shares						127,179,291
Warrants percentage						4%
Marketable securities						$ 2,353,000		$ 3,269,000
Unrealized loss on investment						$ 916,000	$ 1,156,000
DSS Securities, Inc. [Member]
Issuance of common stock, net of expenses					$ 100,000
Outstanding membership interest					10%